Atossa Genetics Company Profile (NASDAQ:ATOS)

About Atossa Genetics (NASDAQ:ATOS)

Atossa Genetics logoAtossa Genetics Inc. is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company's leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has initiated a Phase II clinical study using its microcatheters to deliver fulvestrant as a treatment of ductal carcinoma in-situ (DCIS) and breast cancer. Its second pharmaceutical program under development is Afimoxifene Topical Gel (AfTG) for the treatment and prevention of hyperplasia of the breast. It is also engaged in the process of evaluating other therapeutic candidates to treat other breast conditions, including breast cancer. Its medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator. These devices are intended for the collection of nipple aspirate fluid (NAF) for cytological testing at a laboratory.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ATOS
  • CUSIP: N/A
  • Web:
  • Market Cap: $5.71 million
  • Outstanding Shares: 11,701,000
Average Prices:
  • 50 Day Moving Avg: $0.45
  • 200 Day Moving Avg: $0.62
  • 52 Week Range: $0.32 - $2.60
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.40
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.20 per share
  • Price / Book: 2.42
  • EBIDTA: ($6,590,000.00)
  • Return on Equity: -173.01%
  • Return on Assets: -127.40%
  • Current Ratio: 2.09%
  • Quick Ratio: 2.09%
  • Average Volume: 1.18 million shs.
  • Beta: 1.36
  • Short Ratio: 1.26

Frequently Asked Questions for Atossa Genetics (NASDAQ:ATOS)

What is Atossa Genetics' stock symbol?

Atossa Genetics trades on the NASDAQ under the ticker symbol "ATOS."

How were Atossa Genetics' earnings last quarter?

Atossa Genetics Inc. (NASDAQ:ATOS) released its earnings results on Monday, August, 14th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.20. View Atossa Genetics' Earnings History.

When will Atossa Genetics make its next earnings announcement?

Atossa Genetics is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Atossa Genetics.

Who are some of Atossa Genetics' key competitors?

Who are Atossa Genetics' key executives?

Atossa Genetics' management team includes the folowing people:

  • Steven C. Quay M.D., Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Kyle Guse Esq., CPA, Chief Financial Officer, General Counsel, Secretary
  • Cindy Atha, Vice President of Sales and Marketing
  • Janet Rose Rea MSPH, Vice President - Regulatory Affairs and Quality
  • Shu-Chih Chen Ph.D., Director
  • Stephen J. Galli M.D., Independent Director
  • H. Lawrence Remmel Esq., Independent Director
  • Richard I. Steinhart CPA, Independent Director
  • Gregory L. Weaver, Independent Director

How do I buy Atossa Genetics stock?

Shares of Atossa Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Atossa Genetics' stock price today?

One share of Atossa Genetics stock can currently be purchased for approximately $0.49.

MarketBeat Community Rating for Atossa Genetics (NASDAQ ATOS)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  32 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  63
MarketBeat's community ratings are surveys of what our community members think about Atossa Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Atossa Genetics (NASDAQ:ATOS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Atossa Genetics (NASDAQ:ATOS)
No equities research coverage for this company has been tracked by


Earnings History for Atossa Genetics (NASDAQ:ATOS)
Earnings by Quarter for Atossa Genetics (NASDAQ:ATOS)
Earnings History by Quarter for Atossa Genetics (NASDAQ ATOS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017N/AView Earnings Details
8/14/2017Q2 2017($0.44)($0.64)ViewN/AView Earnings Details
11/14/2016Q316($1.28)$0.07ViewN/AView Earnings Details
8/12/2016Q2($0.07)($0.05)ViewN/AView Earnings Details
5/5/2016Q116($0.07)ViewN/AView Earnings Details
11/12/2015Q315($0.11)($0.15)$2.80 million$0.77 millionViewListenView Earnings Details
8/6/2015Q215($0.12)($0.11)$2.05 million$2.69 millionViewN/AView Earnings Details
5/13/2015Q1($0.11)($0.13)$1.00 million$1.87 millionViewListenView Earnings Details
3/30/2015Q4 2014($0.11)($0.24)$0.10 million$0.49 millionViewN/AView Earnings Details
11/12/2014Q314($0.13)$76.60 million$3.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.23)$0.01 millionViewN/AView Earnings Details
5/14/2014Q114($0.11)($0.10)$1.93 million$0.02 millionViewN/AView Earnings Details
3/27/2014Q4 2013($0.20)($0.15)$0.02 million$0.05 millionViewN/AView Earnings Details
11/12/2013($0.15)($0.22)ViewN/AView Earnings Details
8/14/2013Q213($0.17)$0.28 million$0.33 millionViewN/AView Earnings Details
5/15/2013Q113($0.11)($0.14)$0.52 million$0.18 millionViewN/AView Earnings Details
12/20/2012Q312($0.10)$0.10 million$0.11 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Atossa Genetics (NASDAQ:ATOS)
Current Year EPS Consensus Estimate: $-1.64 EPS
Next Year EPS Consensus Estimate: $-1.23 EPS


Dividend History for Atossa Genetics (NASDAQ:ATOS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Atossa Genetics (NASDAQ:ATOS)
Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 7.95%
Insider Trades by Quarter for Atossa Genetics (NASDAQ:ATOS)
Insider Trades by Quarter for Atossa Genetics (NASDAQ:ATOS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/17/2017H. Lawrence RemmelDirectorBuy2,500$0.63$1,575.00View SEC Filing  
4/1/2016H. Lawrence RemmelDirectorBuy1,500$0.33$495.00View SEC Filing  
3/9/2016Steven C QuayCEOBuy15,000$0.37$5,550.00View SEC Filing  
2/16/2016Shu-Chih ChenDirectorBuy15,000$0.53$7,950.00View SEC Filing  
1/19/2016Steven C QuayCEOBuy50,000$0.20$10,000.00View SEC Filing  
6/12/2015H. Lawrence RemmelDirectorBuy5,400$1.30$7,020.00View SEC Filing  
11/21/2013Gregory L WeaverDirectorBuy10,000$2.58$25,800.00View SEC Filing  
10/1/2013Steven C QuayCEOSell7,265$5.66$41,119.90View SEC Filing  
1/8/2013H. Lawrence RemmelDirectorBuy4,000$4.12$16,480.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Atossa Genetics (NASDAQ:ATOS)
Latest Headlines for Atossa Genetics (NASDAQ:ATOS)
DateHeadline logoBRIEF-Atossa Genetics files for mixed shelf of upto $50 million - September 22 at 11:11 PM logoAtossa Genetics, Endoxifen Phase I Results and Pipeline Review - September 19 at 4:08 PM logoAtossa Genetics (ATOS) On Preliminary Topical Endoxifen Phase 1 Results - Conference - September 15 at 4:31 PM logoAtossa Genetics Announces Preliminary Results From Phase 1 Study Of Topical Endoxifen - September 14 at 9:50 PM logoBRIEF-Atossa Genetics announces preliminary results from Phase 1 study of topical Endoxifen - September 14 at 9:50 PM logoAtossa Genetics Announces Preliminary Results from Phase 1 Study of Topical Endoxifen - September 14 at 4:46 PM logoToday's Research Reports on Stocks to Watch: Atossa Genetics and Forward Pharma - September 13 at 5:22 PM logoAtossa Genetics To Host Conference Call to Announce Preliminary Results from Phase 1 Study of Topical Endoxifen Thursday, September 14, 2017 at 2 pm EDT - September 11 at 4:14 PM logo"Meeting Or Exceeding Expectations" - August 31 at 4:02 PM logoAtossa Genetics Inc. (ATOS) Issues Quarterly Earnings Results - August 15 at 9:41 AM logoAtossa Genetics Announces Second Quarter 2017 Financial Results And Provides Company Update - August 14 at 4:36 PM logoShort Interest in Atossa Genetics Inc. (NASDAQ:ATOS) Expands By 58.1% - August 13 at 1:46 AM logoAtossa Genetics Inc. (NASDAQ:ATOS) to Release Earnings on Thursday - August 3 at 7:10 AM logoVista Partners Publishes July 2017 Macroeconomic & Investment Newsletter - July 27 at 3:54 PM logoAtossa Genetics Completes Enrollment in Endoxifen Phase 1 Study and Provides Update on Fulvestrant Microcatheter Phase 2 Study - July 25 at 4:02 PM logoAtossa Genetics Announces Warrant Exercises - June 30 at 4:15 PM logoAtossa Genetics Receives Positive Safety Committee Assessment of First Cohort Receiving Oral Formulation of Endoxifen in Phase 1 Dose Escalation Study - June 26 at 4:15 PM logoATOS: Balance Sheet Boosted by Recent Financing - June 6 at 3:49 PM logoAtossa Genetics to Present at the LD Micro Invitational on June 6, 2017 - June 1 at 3:58 PM logoAtossa Genetics Completes Enrollment in Topical Arm of Endoxifen Phase 1 Study - May 19 at 9:22 AM logoBRIEF-Atossa Genetics qtrly loss per share $0.45 - May 11 at 9:08 PM logoAtossa Genetics (ATOS) Anounces Second Positive Safety Committee Decision in Phase 1 Topical Endoxifen Dose Escalation Study - May 11 at 1:53 AM logoAtossa Genetics Receives Second Positive Safety Committee Decision in Phase 1 Topical Endoxifen Dose Escalation Study - May 10 at 9:04 AM logoBRIEF-Atossa Genetics receives approval from institutional review board for continuation of its fulvestrant microcatheter phase 2 study - May 9 at 8:44 PM logoAtossa Genetics Receives Approval from Institutional Review Board for Continuation of its Fulvestrant Microcatheter Phase 2 Study - May 9 at 9:06 AM logoAtossa Genetics (ATOS) Receives Daily Media Impact Rating of 0.44 - April 29 at 9:58 AM logoAtossa Genetics Inc (ATOS) Short Interest Down 57.8% in April - April 29 at 7:21 AM logoBRIEF-Atossa receives positive interim review from safety committee in Endoxifen study - April 21 at 8:47 PM logoAtossa Genetics (ATOS) Receives News Sentiment Rating of 0.29 - April 21 at 10:49 AM logoAtossa Genetics Receives Positive Interim Review From Independent Safety Committee in Phase 1 Endoxifen Dose Escalation Study - April 20 at 3:45 PM logoAtossa Genetics (ATOS) Getting Positive Press Coverage, AlphaOne Reports - April 18 at 12:16 PM logoAtossa Genetics (ATOS) Given Daily News Sentiment Rating of 0.31 - April 14 at 5:21 PM logoAtossa Genetics Enrolls First Cohort of Eight Subjects in Endoxifen Study - April 7 at 8:13 AM logoAtossa Genetics Closes Public Offering - April 4 at 4:26 AM logoAtossa Genetics, Inc. Prices $4,000,000 Public Offering - March 29 at 3:54 PM logo3:48 am Atossa Genetics prices $4 mln public offering consisting of units, common stock and warrants - March 29 at 3:54 PM logoSeattle breast cancer company stock plummets as it seeks funding to continue operations - March 29 at 3:54 PM logoAtossa Genetics (ATOS) Confirms Pricing of $4M Public Offering - March 29 at 12:53 PM logoBRIEF-Atossa Genetics prices $4 mln public offering - March 29 at 12:53 PM logoBRIEF-Atossa Genetics files for public offering of up to 4 mln units - March 23 at 4:08 PM logoAtossa Genetics Opens Enrollment in Study of Endoxifen - March 23 at 4:08 PM logoATOSSA GENETICS INC Files SEC form 10-K/A, Annual Report - March 21 at 12:32 PM logoATOSSA GENETICS INC Files SEC form 10-Q/A, Quarterly Report - March 21 at 12:32 PM logoATOS: Pure Player in the Breast Care Space - March 17 at 4:21 PM logoATOSSA GENETICS INC Files SEC form 10-K, Annual Report - March 16 at 5:11 PM logoIPOs & Transactions Week in Review: Feb 13 - 17 / plus "Billion Dollar Questions" M&A whitepaper - February 20 at 3:37 PM logoAtossa Genetics Provides Update on its Phase 2 Study of Fulvestrant Administered with its Microcatheter - January 9 at 4:49 PM logo8:21 am Atossa Genetics transfers the site of its Phase 2 study of fulvestrant in order to facilitate faster enrollment, which co now anticipates completing by August 2017 - January 9 at 4:49 PM logoAtossa Genetics to Present at the 9th Annual Biotech Showcase Conference on January 9, 2017 - January 5 at 9:02 PM logoAtossa Genetics to Present at the 9th Annual LD Micro Main Event Conference on December 7, 2016 - December 1 at 3:45 PM



Atossa Genetics (ATOS) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by Staff